We are live on ! Find out more
LPCN icon

Lipocine
LPCN

Fund managers haven’t disclosed any holdings of LPCN yet.

LPCN Hedge Fund Activity: Q1 2026 in Review

47 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2026, worth a combined $24.9M — up 90% from $13.1M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new LPCN positions and 2 closed out — a net gain of 22 holders — while 9 added to existing stakes and 10 trimmed.

The largest buyer was Ikarian Capital, adding an estimated $2.69M. The largest seller was Diadema Partners, cutting an estimated $1.84M.

  • 47 institutional investors held Lipocine (LPCN) as of Q1 2026, up from 26 in Q4 2025.
  • Funds reported $24.9M of Lipocine stock for Q1 2026, up 90% quarter-over-quarter.
  • 24 funds opened new Lipocine positions in Q1 2026 and 2 closed out, a net change of +22 holders.
  • The largest Lipocine buyer in Q1 2026 was Ikarian Capital, an estimated $2.69M added.
  • The largest Lipocine seller in Q1 2026 was Diadema Partners, an estimated $1.84M sold.

Based on aggregated 13F filings for Q1 2026.